IntroductionThe North America Hunter Syndrome Treatment Market is advancing rapidly with strong investment in biotechnology research, gene therapy development, and patient care infrastructure. Hunter syndrome, or Mucopolysaccharidosis type II (MPS II), is a rare, inherited lysosomal storage disorder caused by a deficiency of the iduronate-2-sulfatase (I2S) enzyme. This enzyme deficiency leads to the accumulation of […]